Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

GGA Software Services, Pfizer to present Indigo ELN at 2013 Bio-IT World Conference and Expo

GGA Software Services LLC, a leading provider of outsourced scientific informatics and software services to the life sciences industry, announced today that GGA and Pfizer will present Indigo ELN, the industry's leading open-source chemistry electronic laboratory notebook, at the 2013 Bio-IT World Conference and Expo in Boston, Massachusetts, on Wednesday, April 10, at 12:00 PM.

From Pfizer, Inc. 10 Apr 2013

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

10 Apr 2013

Bayer HealthCare and German Cancer Research Center to extend strategic alliance in search of novel cancer therapeutics

Bayer HealthCare (Bayer) and the German Cancer Research Center (DKFZ) will extend their successful strategic research alliance in search of novel cancer therapeutics by focusing their activities also on the field of immunotherapy. Immunotherapies are a promising approach to treat cancer with the aim to selectively reactivate the body's own immune system so that it attacks tumor cells.

10 Apr 2013

Research sheds light on malaria-related parasite's transition from acute to chronic stage

A new discovery about the malaria-related parasite Toxoplasma gondii -- which can threaten babies, AIDS patients, the elderly and others with weakened immune function -- may help solve the mystery of how this single-celled parasite establishes life-long infections in people.

10 Apr 2013

New Japan-driven initiative to accelerate research, development innovation for neglected diseases

The Drugs for Neglected Diseases initiative, based in Geneva, Switzerland, and DNDi Japan, based in Tokyo, welcome the launch of the Global Health Innovative Technology Fund, an initiative supported by the Japanese government, several Japanese pharmaceutical companies, and the Bill & Melinda Gates Foundation.

9 Apr 2013

Roche, Isis Pharmaceuticals to develop neurodegenerative therapeutics for Huntington's disease

Roche and Isis Pharmaceuticals, Inc today announced that they have formed an alliance to develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.

9 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

Professor Alex Matter, Chief Executive Officer of A*STAR's Experimental Therapeutics Centre (ETC), has been awarded the 8th Annual Szent-Gy-rgyi Prize for Progress in Cancer Research by the National Foundation for Cancer Research (NFCR) for his contributions to the development of the first drug specifically targeting a molecular lesion in cancer.

7 Apr 2013

New technology provides clear images of brain with Parkinson's without use of intrusive restraints

A technology being developed at Oak Ridge National Laboratory promises to provide clear images of the brains of children, the elderly and people with Parkinson's and other diseases without the use of uncomfortable or intrusive restraints.

5 Apr 2013

UIC College of Pharmacy receives grant to train students in natural product drugs

Elizabeth Martinez hopes to one day discover a cure for menopausal symptoms using an herbal dietary supplement. With the help of a new federal training grant to the University of Illinois at Chicago College of Pharmacy, her vision may become reality.

5 Apr 2013

Scientists develop a new way to generate induced pluripotent stem cell lines from human fibroblasts

A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists led by David Kahler, PhD, NYSCF Director of Laboratory Automation, have developed a new way to generate induced pluripotent stem (iPS) cell lines from human fibroblasts, acquired from both healthy and diseased donors.

4 Apr 2013

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, announced today that it has entered into a global collaboration agreement with Pfizer Inc. to develop and commercialize Accurins utilizing select small molecule targeted therapies.

3 Apr 2013

Sanford-Burnham selects organizations to participate in Florida Translational Research Program

Sanford-Burnham Medical Research Institute at Lake Nona announced the selection of the first five research organizations that will participate in the Florida Translational Research Program to advance drug discovery in the state.

3 Apr 2013

Media outlets examine reaction to India's Supreme Court ruling on Novartis patent case

"In a decisive victory for India's pharmaceutical industry, India's Supreme Court rejected Novartis' patent application for the cancer drug Glivec on Monday, ending a seven-year battle by the Swiss drug maker to get a patent in India on its powerful leukemia drug," Time reports (Mahr, 4/1).

3 Apr 2013

Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

Ensemble Therapeutics today announced that preclinical data showing the advantages of its Ensemblins, novel macrocyclic compounds against challenging drug targets, will be presented at the 245th American Chemical Society National Meeting being held April 7-11, 2013 in New Orleans, LA.

2 Apr 2013

India's Supreme Court rules against Novartis AG in 'landmark' patent case

"India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world will get continued access to cheap versions of lifesaving medicines," the Associated Press reports.

2 Apr 2013

Adenosine Therapeutics to explore strategic options for Stedivaze

Adenosine Therapeutics, LLC, a drug discovery and development company founded in 1999, announced today that it has engaged Needham & Company to explore strategic options for Stedivaze, a highly selective adenosine A2A agonist being developed as a pharmacological stress agent for use in Myocardial Perfusion Imaging.

2 Apr 2013

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its development of Cynviloq (IG-001) at the annual meeting of the American Association for Cancer Research in Washington, DC (April 6th to 10th).

1 Apr 2013

Chromatrap chromatin immunoprecipitation (ChIP) assay range added to Porvair Sciences’ portfolio of products for epigenetics

Porvair Sciences has announced the addition of the novel Chromatrap chromatin immunoprecipitation (ChIP) assay range to its portfolio of products for epigenetics.

From Chromatrap® - Porvair Sciences Ltd 28 Mar 2013

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

Oncodesign, a company specializing in drug discovery and providing pharmacological evaluation services in the field of oncology, today announces that it has signed a second research collaboration agreement with Sanofi.

27 Mar 2013

Drug Discovery News and Research

Further Reading

GGA Software Services, Pfizer to present Indigo ELN at 2013 Bio-IT World Conference and Expo

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Bayer HealthCare and German Cancer Research Center to extend strategic alliance in search of novel cancer therapeutics

Research sheds light on malaria-related parasite's transition from acute to chronic stage

New Japan-driven initiative to accelerate research, development innovation for neglected diseases

Roche, Isis Pharmaceuticals to develop neurodegenerative therapeutics for Huntington's disease

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

New technology provides clear images of brain with Parkinson's without use of intrusive restraints

UIC College of Pharmacy receives grant to train students in natural product drugs

Scientists develop a new way to generate induced pluripotent stem cell lines from human fibroblasts

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

Sanford-Burnham selects organizations to participate in Florida Translational Research Program

Media outlets examine reaction to India's Supreme Court ruling on Novartis patent case

Ensemble Therapeutics to highlight IL-17A inhibitor Ensemblin at 245th ACS National Meeting

India's Supreme Court rules against Novartis AG in 'landmark' patent case

Adenosine Therapeutics to explore strategic options for Stedivaze

IGDRASOL to present updates on Cynviloq at AACR annual meeting

Chromatrap chromatin immunoprecipitation (ChIP) assay range added to Porvair Sciences’ portfolio of products for epigenetics

Oncodesign signs agreement with Sanofi to identify kinase inhibitors involved in tissue protection and repair

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News